Akero Therapeutics to Announce New Data from an Evaluation of Efruxifermin (EFX) in Cirrhotic NASH (F4) Patients

Rhea-AI Summary

Akero Therapeutics, Inc. (Nasdaq: AKRO) announced plans to discuss new efficacy and safety data from the expansion cohort of its Phase 2a clinical trial for efruxifermin (EFX), aimed at treating adults with cirrhotic non-alcoholic steatohepatitis (NASH). The update, including biopsy results, will be presented in a press release and a webcast on March 22, 2021, at 4:30 p.m. ET. Akero is focused on developing treatments for NASH, a condition without current approved therapies.

Positive

• New efficacy and safety data from a Phase 2a clinical trial could indicate significant progress for EFX treatment in NASH.
• Cohort C results may enhance investor confidence and interest in Akero's ongoing NASH research.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that the company plans to discuss new efficacy and safety data, including biopsy results, from an expansion cohort of a 16-week Phase 2a clinical trial, Cohort C, evaluating efruxifermin (EFX) in the treatment of adult patients with cirrhotic nonalcoholic steatohepatitis (NASH) in a post-market press release and webcast to be held today, March 22, 2021.

Conference Call / Webcast Details
The company will host a conference call and webcast with slide presentation at 4:30 p.m. ET (1:30 p.m. PT) this afternoon, March 22, 2021. The webcast of the conference call will be made available on the company's website at www.akerotx.com under the Investors tab in the Events, Presentations & Webcasts section. To access the call via dial-in, please dial 1-877-282-0556 (U.S. toll free) or 1-270-215-9899 (international), Conference ID 1885464, five minutes prior to the start time. Following the live audio webcast, a replay will be available on the company's website for 90 days.

About Akero Therapeutics
Akero Therapeutics is a clinical-stage cardio-metabolic company developing transformational treatments for non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Akero's lead product candidate, EFX, an engineered Fc-FGF21 fusion protein, is currently being evaluated in Phase 2 clinical trials as a potential treatment for NASH. Akero is headquartered in South San Francisco. Visit us at www.akerotx.com for more information.

Investor Contact:
Christina Tartaglia
212.362.1200
IR@akerotx.com

Media Contact:
Jennifer Weismann
612.716.0556
media@akerotx.com

 

FAQ

What are the key data points being discussed by Akero Therapeutics regarding EFX on March 22, 2021?

Akero is discussing new efficacy and safety data, including biopsy results from the Cohort C of its Phase 2a clinical trial for EFX in treating cirrhotic NASH.

What is the significance of the Phase 2a trial results for Akero's stock (AKRO)?

Positive results from the Phase 2a trial could boost investor confidence and potentially increase the stock's value, given the lack of approved therapies for NASH.

When will the Akero Therapeutics webcast and conference call take place?

The webcast and conference call will take place on March 22, 2021, at 4:30 p.m. ET.

How can investors access the Akero Therapeutics conference call?

Investors can access the call via dial-in at 1-877-282-0556 (U.S. toll free) or 1-270-215-9899 (international) with Conference ID 1885464.

Where can I find more information about Akero Therapeutics?

More information about the company and its developments can be found on their website at www.akerotx.com.